FDA Rejects Replimune's Cancer Therapy RP1 Again, Citing Manufacturing Concerns

Replimune's repeated rejection by the FDA signifies significant regulatory hurdles and skepticism over its lead therapy's efficacy. The company's stock plummeted 64%, reflecting investor concern and potential delays in cancer treatment development. Moving forward, Replimune must address manufacturing issues and demonstrate clearer efficacy to regain approval chances.